ALFA Finder| Value | ₹2.23 Cr |
|---|---|
| Execution period | April 7, 2026 |
BSE filing, NSE: DRREDDY. Summary written from the filing by ALFA Finder's alert engine.
Dr. Reddy's Laboratories Ltd: key numbers
- Share price
- ₹1,377.00
- Market cap
- ₹1,14,935 Cr
- Revenue (annual)
- ₹33,700 Cr
- Net profit (annual)
- ₹4,196 Cr
- P/E (TTM)
- 41.0×Sector 43.8×
- Promoter holding
- 26.63%-0.01% QoQ
- FII holding
- 20.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Dr. Reddy's Laboratories Ltd
All →Dr. Reddy's Laboratories Regulatory Approval
Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.
Dr. Reddy's Laboratories Other Announcement
Dr Reddy's KMP Erez Israeli sold 460,276 ADRs to cover the exercise of 591,270 ADRs allotted under ESOP. The disposal is valued at about ₹61.76 Crore.
- Value
- ₹61.76 Cr
Dr. Reddy's Laboratories Employee Stock Options
Dr. Reddy's allotted 5,91,270 equity shares to employees on exercise of stock options under its ADR ESOP Scheme 2007. Exercise prices ranged from Re.1 to Rs.1,060.20 per share.
Dr. Reddy's Laboratories Price Movement Clarification
Dr. Reddy's confirms FDA tentative approval for its lenacapavir HIV shot. The company states the news is not material and has no material impact.
Dr. Reddy's Laboratories Business Update
Dr Reddy's says USFDA closed its PAI and GMP inspection at Srikakulam FTO-SEZ Process Unit-02 with VAI classification. The outcome is closed with no monetary penalty.
Dr. Reddy's Laboratories Earnings Call Transcript: Key Takeaways
Revenue declined 1.5% YoY as lower Revlimid sales in North America offset strong double-digit growth in base business and emerging markets.
- Call
- Guides 25% growth
Other merger & restructuring announcements
All →Zydus Lifesciences Merger & Restructuring
Zydus completed its subscription for 50% of Zydus Sunshine, making it a 50:50 joint venture with Sunshine Healthcare Lanka. Completed November 11, 2026.
Spacenet Enterprises India Merger & Restructuring Worth ₹2.6 Cr
Spacenet sold 40,00,005 String Metaverse shares on 11 November 2026 at ₹6.49 each. Gross consideration of about ₹2.60 Crore is disclosed as material.
- Value
- ₹2.60 Cr
Abans Financial Services Merger & Restructuring Worth ₹1.2 Cr
Abans Financial Services approved incorporating a Hong Kong subsidiary for bullion and securities trading. The cash consideration is Rs 1.20 Crore.
- Value
- ₹1.20 Cr
Adani Enterprises Merger & Restructuring Worth ₹0.94 Cr
Adani Enterprises reported incorporation of Adani Rovuma Chemicals Limited in UAE on November 10, 2026, via Adani Global Limited. Cash consideration of Rs. 0.94 Crore was stated.
- Value
- ₹0.94 Cr
Adani Enterprises Merger & Restructuring
Adani Enterprises' subsidiary Adani Global incorporated Adani Rovuma Chemicals Limited in UAE on November 10, 2026. It is a step-down subsidiary with USD 100,000 paid-up capital.
Kovai Medical Center and Hospital Merger & Restructuring Worth ₹0.85 Cr
Kovai Medical extended the completion deadline for the slump sale of its AHS division to a related-party trust to January 31, 2027. Cash consideration is Rs.84.54 Lakhs.
- Value
- ₹0.85 Cr
- Execution
- Completion expected by 31 January 2027